Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal ArticleDOI
IDO expression by dendritic cells: tolerance and tryptophan catabolism.
Andrew L. Mellor,David H. Munn +1 more
TL;DR: This review summarizes key recent developments and proposes a unifying model for the role of IDO in tolerance induction, including studies of mammalian pregnancy, tumour resistance, chronic infections and autoimmune diseases.
Journal ArticleDOI
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Diana Miao,Diana Miao,Bastian Schilling,Sachet A. Shukla,Sachet A. Shukla,Christian U. Blank,Lisa Zimmer,Antje Sucker,Uwe Hillen,Marnix H Geukes Foppen,Simone M. Goldinger,Jochen Utikal,Jochen Utikal,Jessica C. Hassel,Benjamin Weide,Katharina C. Kaehler,Carmen Loquai,Peter Mohr,Ralf Gutzmer,Reinhard Dummer,Stacey Gabriel,Catherine J. Wu,Catherine J. Wu,Dirk Schadendorf,Levi A. Garraway,Levi A. Garraway +27 more
TL;DR: Investigating the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab found no recurrent neoantigen peptide sequences predicted responder patient populations, suggesting detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.
Journal ArticleDOI
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
TL;DR: The mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy is identified, pointing to new candidate targets for immune potentiation.
Journal ArticleDOI
The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.
TL;DR: This review discusses major advances in the understanding of the regulation of DC lineage commitment, differentiation, diversification, and function in situ.
Journal ArticleDOI
Antigen Presentation and T Cell Stimulation by Dendritic Cells
TL;DR: Dendritic cells take up antigens in peripheral tissues, process them into proteolytic peptides, and load these peptides onto major histocompatibility complex (MHC) class I and II molecules, thus initiating antigen-specific immune responses, or immunological tolerance.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more